- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00609999
Ph I Dasatinib + Erlotinib in Recurrent MG
Phase I Study of Dasatinib Plus Erlotinib in Recurrent Malignant Glioma
Primary:
To determine maximum tolerated dose & dose limiting toxicity of dasatinib when combined w erlotinib among pts w recurrent MG
Secondary:
To further evaluate safety & tolerability of dasatinib + erlotinib To evaluate pharmacokinetics of dasatinib when administered w erlotinib among recurrent MG pts who are on & not on CYP-3A enzyme inducing anti-epileptic drugs To evaluate for anti-tumor activity with this regimen in this patient population
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Tarceva administered on continuous oral dosing schedule at 150 mg/day for pts not on EIAEDs & 450 mg/day for pts on EIAEDs. Starting dose level of dasatinib will be 100 mg once day via continuous oral daily dosing. Dasatinib will be increased in successive cohorts of enrolled pts. Pts will remain on treatment until excessive toxicity, progressive disease, withdrawal of consent/death.
Pts have confirmed diagnosis of recurrent/progressive WHO gr IV MG / WHO grade III MG. Phase I 3+3 dose escalation design w 2 independently escalated stratum: stratum A-pts not on CYP3A-enzyme inducing anti-epileptic drugs; stratum B-pts on EIAEDs. Assessment of safety will be based mainly on frequency of adverse events, particularly adverse events leading to discontinuation of treatment & on number of significant lab abnormalities.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Duke University Health System
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Diagnosis of recurrent/progressive WHO grade IV MG or WHO grade III MG. Pts with prior low-grade glioma are eligible if histologic assessment demonstrates transformation to WHO grade III / IV MG
- >18 yrs
- Karnofsky Performance Status >70 percent
- Pts presenting in 1st, 2nd / 3rd relapse. Prior therapy must have included external beam XRT
- Adequate bone marrow, liver & renal function as assessed by following:
- Hemoglobin>9.0g/dl
- ANC>1,500/mm3
- Platelet count>100,000/mm3
- Total bilirubin<1.5 x ULN
- ALT & AST<2.5 x ULN
- INR<1.5 or PT/PTT within normal limits. Pts receiving anti-coagulation treatment w low-molecular weight heparin allowed to participate, oral warfarin is not permitted
- Creatinine<1.5 x ULN
- Serum Na, K+, Mg2+, Phosphate & Ca2+ >LLN
- Interval<2 wks between prior surgical resection & initiation of study regimen
- Interval <12 weeks from completion of standard, daily XRT, unless one of following occurs: new area of enhancement on MRI imaging that is outside XRT field; biopsy proven recurrent tumor; / radiographic evidence of progressive tumor on 2 consecutive scans >4 wks apart.
- Interval <4weeks from prior chemotherapy unless there is unequivocal evidence of tumor progression & pt has recovered from all anticipated toxicities from prior therapy
- Interval <4weeks from prior investigational agent unless there is unequivocal evidence of tumor progression & pt has recovered from all anticipated toxicities from prior therapy
- Signed written informed consent including HIPAA according to institutional guidelines. Signed informed consent must be obtained prior to any study specific procedures
- If sexually active, pts will take contraceptive measures for duration of treatments & for 4 weeks following discontinuation of dasatinib & Erlotinib.
- Women of childbearing potential must have negative serum or urine pregnancy test within 72 hrs prior to start of study drug administration
Exclusion Criteria:
- No prior dasatinib / oral EGFR-inhibitor therapy
- Pregnancy/breast feeding
History of significant concurrent illness
->3 prior episodes of progressive disease
- Significant cardiac disease
- Excessive risk of bleeding as defined by stroke <6 months, history of CNS / intraocular bleed,/ septic endocarditis.
- Concurrent severe and/or uncontrolled medical disease that could compromise participation in study including any of following: pleural / pericardial effusion of any grade; uncontrolled diabetes; uncontrolled hypertension; active clinically serious infection >CTCAEv3 Gr2 requiring active intervention; history of clinically-significant bleeding diathesis or coagulopathy including platelet function disorder or acquired bleeding disorder within 1yr; impairment of GI function /GI disease that may significantly alter absorption of study regimen; ongoing or recent significant gastrointestinal bleeding
- Thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks <6 months
- Any hemorrhage/bleeding event >CTCAEv3AE Gr3 within 4wks of 1st dose of study drug
- Serious non-healing wound, ulcer, /bone fracture
- Major surgery, open biopsy /significant traumatic injury <4 weeks of 1st study drug
- Known HIV infection/chronic Hepatitis B/C
- Pt is <3yrs free of another primary malignancy except: if other primary malignancy is either not currently clinically significant/does not require active intervention. Existence of any other malignant disease is not allowed.
- Pts unwilling to/unable to comply with protocol including ability to swallow whole pills/presence of any malabsorption syndrome
- Concurrent administration of warfarin, rifampin/St. John's Wort
- Subjects w hypokalemia/hypomagnesemia if it cannot be corrected
- Prisoners/subjects who are compulsorily detained for treatment of either psychiatric/physical illness
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Stratum A
Pts not on EIAEDs
|
You will begin study drug regimen on day 1 of cycle 1 w Dasatinib.
If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected.
Erlotinib will be begin after initial Dasatinib PK assessments are collected & will continue to be administered w Dasatinib on continuous daily dosing schedule.
Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 & at end of cycle 1.
If you are not undergoing Dasatinib PK collections you will begin both Dasatinib & Erlotinib together on day 1 of cycle 1.
Both drugs will be given in continuous daily oral manner.
Cycle is defined as Dasatinib & Erlotinib given daily for 28 days for purpose of scheduling evaluations.
Autres noms:
|
Expérimental: Stratum B
Pts on EIAEDs
|
You will begin study drug regimen on day 1 of cycle 1 w Dasatinib.
If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected.
Erlotinib will be begin after initial Dasatinib PK assessments are collected & will continue to be administered w Dasatinib on continuous daily dosing schedule.
Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 & at end of cycle 1.
If you are not undergoing Dasatinib PK collections you will begin both Dasatinib & Erlotinib together on day 1 of cycle 1.
Both drugs will be given in continuous daily oral manner.
Cycle is defined as Dasatinib & Erlotinib given daily for 28 days for purpose of scheduling evaluations.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
To determine MTD & DLT of Dasatinib when combined w Erlotinib among pts w Recurrent MG
Délai: 12 months
|
12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
To further evaluate safety & tolerability of Dasatinib + Erlotinib
Délai: 12 months
|
12 months
|
To evaluate the PK of Dasatinib when administered w Erlotinib among Recurrent MG pts who are on & not on EIAEDs
Délai: 12 months
|
12 months
|
To evaluate for anti-tumor activity w this regimen in this pt population
Délai: 12 months
|
12 months
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Tumeurs
- Tumeurs, glandulaires et épithéliales
- Astrocytome
- Gliome
- Tumeurs, neuroépithéliales
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Glioblastome
- Gliosarcome
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Inhibiteurs de protéine kinase
- Chlorhydrate d'erlotinib
- Dasatinib
Autres numéros d'identification d'étude
- Pro00002272
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Erlotinib and Dasatinib
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbComplétéCarcinome pulmonaire non à petites cellulesÉtats-Unis
-
hearX GroupUniversity of PretoriaComplété
-
Oregon Health and Science UniversityNational Institute on Aging (NIA)ComplétéDémence | Maladie d'Alzheimer | Membres de la famille | Épuisement professionnel des soignantsÉtats-Unis
-
Dalarna UniversityUppsala University; The Swedish Research CouncilRecrutementDémence | Déficience cognitive légère | Démence mixte | Démence de type Alzheimer | Déficience cognitive subjective | Démence SénileSuède
-
M.D. Anderson Cancer CenterComplété
-
University of Illinois at Urbana-ChampaignInconnueBlessure de chute | Prévention des chutes | Sécurité antichute
-
Samsung ElectronicsComplétéVieilli | Adultes | Moyen-Âge | Âgé, 80 ans et plusCorée, République de
-
Institut du Cancer de Montpellier - Val d'AurelleUniversity Hospital, Clermont-Ferrand; Laboratoire EPSYLON; Academic resource...Complété
-
Eunice Kennedy Shriver National Institute of Child...Inconnue
-
University of Illinois at ChicagoComplétéPersonnes âgées en bonne santéÉtats-Unis